Cantor Fitzgerald and Kristen Kluska to Host Zoom Fireside Chat with Ocugen
October 16 2020 - 7:30AM
Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on
discovering, developing, and commercializing transformative
therapies to cure blindness diseases, today announced that Cantor
Fitzgerald and Kristen Kluska will host a Management Fireside Chat
Zoom Call on October 21 at 11 a.m. ET.
Ocugen management, including Dr. Shankar Musunuri, Chairman,
CEO, and Co-Founder, Sanjay Subramanian, CFO, Dr. Mohamed Genead,
Acting CMO and Chair of the Scientific Advisory Board, and Dr. Mark
Pennesi, Scientific Advisory Board Member, will discuss Ocugen’s
lead program, OCU400 (AAV-NR2E3), a modifier gene therapy indicated
for retinal degeneration disorders. In addition, they will provide
highlights from the clinical, histological, and functional outcomes
as published in Nature Gene Therapy evaluating AAV-NR2e3. They will
also provide retina and disease backgrounds of members of the
Retina Scientific Advisory Board. Lastly, they will provide an
update on their goal of initiating two clinical trials in 2021 for
OCU400 and expanding into four clinical trials in 2022 with OCU410
(AAV-RORA) for the treatment of dry age-related macular
degeneration and OCU200, a biologic product candidate in
preclinical development for treating severely sight-threatening
diseases like Diabetic Macular Edema, Diabetic Retinopathy, and Wet
Age-Related Macular Degeneration.
Cantor Fitzgerald initiated analyst coverage of Ocugen with an
“Overweight” rating and a price target of $1.00 on October 9, based
on its potential of AAV-based gene therapies and the belief that
the eye is one of the most well understood target organs. All
reports on Ocugen prepared by analysts represent the views of those
analysts and not necessarily those of Ocugen. Ocugen is not
responsible for the content, accuracy, or timing of analyst
reports. A copy of the full analyst note can be obtained directly
from Cantor Fitzgerald.
Call
Details:Cantor Fitzgerald
Fireside Chat with Ocugen
Date: Wednesday, October 21,
2020Time: 11 AM (Eastern
Time)Pre-Register for Call:
https://us02web.zoom.us/webinar/register/WN_V3oYtzu5SwqMsoLgDvvqKA
About Ocugen, Inc.Ocugen, Inc. is a
biopharmaceutical company focused on discovering, developing, and
commercializing transformative therapies to cure blindness
diseases. Our breakthrough modifier gene therapy platform has the
potential to treat multiple retinal diseases with one drug – “one
to many” and our novel biologic product candidate aims to offer
better therapy to patients with underserved diseases such as wet
age-related macular degeneration, diabetic macular edema, and
diabetic retinopathy. For more information, please visit
www.ocugen.com.
Cautionary Note on Forward-Looking
StatementsThis press release contains forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995, which are subject to risks and uncertainties.
We may, in some cases, use terms such as “predicts,” “believes,”
“potential,” “proposed,” “continue,” “estimates,” “anticipates,”
“expects,” “plans,” “intends,” “may,” “could,” “might,” “will,”
“should” or other words that convey uncertainty of future events or
outcomes to identify these forward-looking statements. Such
statements are subject to numerous important factors, risks and
uncertainties that may cause actual events or results to differ
materially from our current expectations. These and other risks and
uncertainties are more fully described in our periodic filings with
the Securities and Exchange Commission (the “SEC”), including the
risk factors described in the section entitled “Risk Factors” in
the quarterly and annual reports that we file with the SEC. Any
forward-looking statements that we make in this press release speak
only as of the date of this press release. Except as required by
law, we assume no obligation to update forward-looking statements
contained in this press release whether as a result of new
information, future events or otherwise, after the date of this
press release.
Corporate Contact:Ocugen,
Inc.Sanjay SubramanianChief Financial
Officerir@ocugen.comMedia
Contact:LaVoieHealthScienceKatie
Gallagherkgallagher@lavoiehealthscience.com+1 617-792-3937
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Sep 2023 to Sep 2024